Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels

We previously showed that variant SLCO1B1 haplotype *1b (A388G) accelerates and that *5 (T521C) delays hepatocellular uptake of the HMG-CoA reductase inhibitor pravastatin [Mwinyi et al. (2004): Clin Pharmacol Ther 75:415-421]. In the present study we checked for differential effects of variant SLCO...

Full description

Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology, Vol. 373, No. 1 (2006), p. 45-50
Main Author: Gerloff, Thomas (Author)
Other Involved Persons: Schaefer, Melanie ; Mwinyi, Jessica ; Johne, Andreas ; Sudhop, Thomas ; Lütjohann, Dieter ; Roots, Ivar ; von Bergmann, Klaus
Format: Article
Item Description:Date Completed 25.11.2008
Date Revised 01.12.2018
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Other Editions:Show all 2 Editions
QR Code: Show QR Code